Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer

Publication ,  Journal Article
Armstrong, AJ; Gingrich, JR; Haggman, M; Stadler, WM; Damber, JE; Belkoff, L; Clark, R; Brosman, S; Nordle, O; Forsberg, G; Carducci, MA; Pili, R
Published in: EUROPEAN UROLOGY SUPPLEMENTS
February 1, 2012

Duke Scholars

Published In

EUROPEAN UROLOGY SUPPLEMENTS

ISSN

1569-9056

Publication Date

February 1, 2012

Volume

11

Issue

1

Start / End Page

E126 / U515

Publisher

ELSEVIER SCIENCE BV

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Gingrich, J. R., Haggman, M., Stadler, W. M., Damber, J. E., Belkoff, L., … Pili, R. (2012). Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E126-U515.
Armstrong, A. J., J. R. Gingrich, M. Haggman, W. M. Stadler, J. E. Damber, L. Belkoff, R. Clark, et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” EUROPEAN UROLOGY SUPPLEMENTS 11, no. 1 (February 1, 2012): E126-U515.
Armstrong AJ, Gingrich JR, Haggman M, Stadler WM, Damber JE, Belkoff L, et al. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS. 2012 Feb 1;11(1):E126-U515.
Armstrong, A. J., et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” EUROPEAN UROLOGY SUPPLEMENTS, vol. 11, no. 1, ELSEVIER SCIENCE BV, Feb. 2012, pp. E126-U515.
Armstrong AJ, Gingrich JR, Haggman M, Stadler WM, Damber JE, Belkoff L, Clark R, Brosman S, Nordle O, Forsberg G, Carducci MA, Pili R. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS. ELSEVIER SCIENCE BV; 2012 Feb 1;11(1):E126-U515.
Journal cover image

Published In

EUROPEAN UROLOGY SUPPLEMENTS

ISSN

1569-9056

Publication Date

February 1, 2012

Volume

11

Issue

1

Start / End Page

E126 / U515

Publisher

ELSEVIER SCIENCE BV

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences